Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations

American Journal of Hematology

Volumn 84, Issue 10, 2009, Pages 629-630

  Tefferi, Ayalew ^a   Passamonti, Francesco ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; HYDROXYUREA; LOW MOLECULAR WEIGHT HEPARIN;

FIRST TRIMESTER PREGNANCY; GENE MUTATION; HUMAN; INCIDENCE; LOW DRUG DOSE; NOTE; PREGNANCY; PRIORITY JOURNAL; SECOND TRIMESTER PREGNANCY; SPONTANEOUS ABORTION; THROMBOCYTHEMIA;

ASPIRIN; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; HYDROXYUREA; INTERFERON TYPE I, RECOMBINANT; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; THROMBOCYTHEMIA, ESSENTIAL;

EID: 70349479426     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21508     Document Type: Note

References (24)

1. Selinger HA, Ma X. Jakking up tumor registry reporting of the myeloproliferative neoplasms. Am J Hematol 2009;84:124-126.
2. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.
3. Girodon F, Bonicelli G, Schaeffer C, et al. Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: A population-based study. Haematologica 2009;94:865-869.
4. Landgren O, Goldin LR, Kristinsson SY, et al. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood 2008;112:2199-2204.
5. Tefferi A. Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapy. Am J Hematol 2008;83:491-497. (Pubitemid 351742799)
6. Palandri F, Catani L, Testoni N, et al. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. Am J Hematol 2009;84:215-220.
7. Tefferi A, Gangat N, Wolanskyj AP, et al. 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: Predictors at diagnosis. Eur J Haematol 2008;80:386-390.
8. Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: A study of 605 patients. Haematologica 2008;93:1645-1651.
9. Norgard B, Puho E, Czeizel AE, Skriver MV, Sorensen HT. Aspirin use during early pregnancy and the risk of congenital abnormalities: A population-based case-control study. Am J Obstet Gynecol 2005;192:922-923. (Pubitemid 40311290)
10. Kozer E, Costei AM, Boskovic R, Nulman I, Nikfar S, Koren G. Effects of aspirin consumption during pregnancy on pregnancy outcomes: Meta-analysis. Birth Defects Res B Dev Reprod Toxicol 2003;68:70-84. (Pubitemid 37248105)
11. CLASP: A randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women.CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet 1994;343:619-629.
12. Budde U, van Genderen PJ. Acquired von Willebrand disease in patients with high platelet counts. Semin Thromb Hemost 1997;23:425-431. (Pubitemid 27501782)
13. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45. (Pubitemid 41007805)
14. Elliott MA, Tefferi A. Thrombocythaemia and pregnancy. Best Pract Res Clin Haematol 2003;16:227-242.
15. Liebelt EL, Balk SJ, Faber W, et al. NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea. Birth Defects Res B Dev Reprod Toxicol 2007;80:259-366. (Pubitemid 350194528)
16. Passamonti F, Randi ML, Rumi E, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood 2007;110:485-489.
17. Gangat N, Wolanskyj AP, Schwager S, Tefferi A. Predictors of pregnancy outcome in essential thrombocythemia: A single institution study of 63 pregnancies. Eur J Haematol 2009;82:350-353.
18. Niittyvuopio R, Juvonen E, Kaaja R, et al. Pregnancy in essential thrombocythaemia: Experience with 40 pregnancies. Eur J Haematol 2004;73:431-436. (Pubitemid 39564367)
19. Melillo L, Tieghi A, Candoni A, et al. Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry. Am J Hematol, in press.
20. Bangerter M, Guthner C, Beneke H, et al. Pregnancy in essential thrombocythaemia: Treatment and outcome of 17 pregnancies. Eur J Haematol 2000;65:165-169. (Pubitemid 30682715)
21. Pagliaro P, Arrigoni L, Muggiasca ML, et al. Primary thrombocythemia and pregnancy: Treatment and outcome in fifteen cases. Am J Hematol 1996;53:6-10. (Pubitemid 26340430)
22. Laskin CA, Spitzer KA, Clark CA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: Results from the randomized, controlled HepASA trial. J Rheumatol 2009;36:279-287.
23. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients. Blood 2006;108:3472-3476. (Pubitemid 44776889)
24. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009;23:905-911.